EXICURE, INC. Restricted Cash and Cash Equivalents, Noncurrent
EXICURE, INC. (XCUR) had Restricted Cash and Cash Equivalents, Noncurrent of $0 as of 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Restricted Cash and Cash Equivalent, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2025-03-18
- 2024-12-31: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2023-12-31: Restricted Cash and Cash Equivalents, Noncurrent $1.20M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-18 |
| 2023-12-31 | $1.20M 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |